Copyright © 2008 The American Society of Human Genetics. All rights reserved.
The American Journal of Human Genetics, Volume 82, Issue 4, 834-848, 28 March 2008
doi:10.1016/j.ajhg.2008.01.014
Article
Antisense Masking of an hnRNP A1/A2 Intronic Splicing Silencer Corrects SMN2 Splicing in Transgenic Mice
Yimin Hua1, Timothy A. Vickers2, Hazeem L. Okunola1, C. Frank Bennett2 and Adrian R. Krainer1, 
, 
1 Cold Spring Harbor Laboratory, PO Box 100, Cold Spring Harbor, NY 11724, USA
2 Isis Pharmaceuticals, 1896 Rutherford Road, Carlsbad, CA 92008, USA
Corresponding authorAbstract
survival of motor neuron 2, centromeric (SMN2) is a gene that modifies the severity of spinal muscular atrophy (SMA), a motor-neuron disease that is the leading genetic cause of infant mortality. Increasing inclusion of SMN2 exon 7, which is predominantly skipped, holds promise to treat or possibly cure SMA; one practical strategy is the disruption of splicing silencers that impair exon 7 recognition. By using an antisense oligonucleotide (ASO)-tiling method, we systematically screened the proximal intronic regions flanking exon 7 and identified two intronic splicing silencers (ISSs): one in intron 6 and a recently described one in intron 7. We analyzed the intron 7 ISS by mutagenesis, coupled with splicing assays, RNA-affinity chromatography, and protein overexpression, and found two tandem hnRNP A1/A2 motifs within the ISS that are responsible for its inhibitory character. Mutations in these two motifs, or ASOs that block them, promote very efficient exon 7 inclusion. We screened 31 ASOs in this region and selected two optimal ones to test in human SMN2 transgenic mice. Both ASOs strongly increased hSMN2 exon 7 inclusion in the liver and kidney of the transgenic animals. Our results show that the high-resolution ASO-tiling approach can identify cis-elements that modulate splicing positively or negatively. Most importantly, our results highlight the therapeutic potential of some of these ASOs in the context of SMA.
Article Information
PubMed
Related Articles
- SMN Dosage Analysis and Risk Assessment for Spinal Muscular ...SMN Dosage Analysis and Risk Assessment for Spinal Muscular Atrophy
The American Journal of Human Genetics, Volume 70, Issue 6, 1 June 2002, Pages 1596-1598
Shuji Ogino and Robert B. Wilson
| - Reply to Ogino and WilsonReply to Ogino and Wilson
The American Journal of Human Genetics, Volume 70, Issue 6, 1 June 2002, Pages 1598-1599
Markus Feldkötter, Verena Schwarzer, Radu Wirth, Thomas F. Wienker and Brunhilde Wirth
| - Determinants of Exon 7 Splicing in the Spinal Muscular Atrop...Determinants of Exon 7 Splicing in the Spinal Muscular Atrophy Genes, SMN1 and SMN2
The American Journal of Human Genetics, Volume 78, Issue 1, 1 January 2006, Pages 63-77
Luca Cartegni, Michelle L. Hastings, John A. Calarco, Elisa de Stanchina and Adrian R. Krainer
AbstractSpinal muscular atrophy is a neurodegenerative disorder caused by the deletion or mutation of the survival-of-motor-neuron gene, SMN1. An SMN1 paralog, SMN2, differs by a C→T transition in exon 7 that causes substantial skipping of this exon, such that SMN2 expresses only low levels of functional protein. A better understanding of SMN splicing mechanisms should facilitate the development of drugs that increase survival motor neuron (SMN) protein levels by improving SMN2 exon 7 inclusion. In addition, exonic mutations that cause defective splicing give rise to many genetic diseases, and the SMN1/2 system is a useful paradigm for understanding exon-identity determinants and alternative-splicing mechanisms. Skipping of SMN2 exon 7 was previously attributed either to the loss of an SF2/ASF–dependent exonic splicing enhancer or to the creation of an hnRNP A/B–dependent exonic splicing silencer, as a result of the C→T transition. We report the extensive testing of the enhancer-loss and silencer-gain models by mutagenesis, RNA interference, overexpression, RNA splicing, and RNA-protein interaction experiments. Our results support the enhancer-loss model but also demonstrate that hnRNP A/B proteins antagonize SF2/ASF–dependent ESE activity and promote exon 7 skipping by a mechanism that is independent of the C→T transition and is, therefore, common to both SMN1 and SMN2. Our findings explain the basis of defective SMN2 splicing, illustrate the fine balance between positive and negative determinants of exon identity and alternative splicing, and underscore the importance of antagonistic splicing factors and exonic elements in a disease context.
Abstract | | - …more
